FDA Approval for Denali Therapeutics Blazes a New Trail for Brain-Penetrating Drugs

Denali Therapeutics’ Avlayah received FDA approval for treating Hunter syndrome, a rare neurological disorder. The biologic medicine uses Denali’s proprietary drug delivery technology to cross the protective blood-brain barrier.

The post FDA Approval for Denali Therapeutics Blazes a New Trail for Brain-Penetrating Drugs appeared first on MedCity News.

Leave a Reply

Your email address will not be published. Required fields are marked *